Emerald Health Therapeutics Files 17 Patent Applications Covering Defined Dose™ Cannabis Products
October 16 2018 - 7:00AM
Unique Emerald cannabinoid formulations
and dosage forms focused on providing consumers precise and
differentiated products based on protected intellectual
property
Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH;
OTCQX:EMHTF) has filed 17 provisional US patent applications
covering Emerald’s unique Defined Dose™ cannabis dosage forms and
formulations. Based on proprietary Emerald research, these patent
applications are contributing to Emerald’s intellectual property
portfolio and its intent to develop distinctive cannabis products
for medical-use and improved adult-use. The products provide
more precise and consistent delivery, dosage, and formulations.
Defined Dose™ cannabis products will, when made available to the
public, provide consumers with products currently not available.
The seventeen Defined Dose™ cannabis patent
applications relate to:
- Inhaled dosage forms for smoking
- Inhaled dosage forms for vaping; and
- Capsule and edible formulations and dosage forms based on a
novel understanding of cannabinoid molecular pathways and how they
influence disease mechanisms.
Certain of the Defined Dose™ cannabis products
are eligible for launch in Canada under existing Canadian
regulations. Others are expected to be eligible under anticipated
regulatory changes in 2019.
“We expect significant potential cannabis market
growth by offering adult users and medical consumers consistent
product characteristics, dosing regimens, and alternative methods
of consumption, with safety enhanced through GMP-compliant
production and enhanced product utility achieved through knowledge
of science. Emerald’s filing of these patent applications is an
important step,” said Chris Wagner, CEO of Emerald. “Our expanding
research and development effort is focused on internal facilities
and staff as well as forming key relationships with other cannabis
research experts, such as our recently announced agreement with
VivaCell Biotechologies Espana.”
“Emerald’s intent is to be at the forefront of
understanding the mechanism of action of the endocannabinoid system
and developing proprietary products that enable both medical and
adult-use consumers to achieve measured outcomes with well
characterized, reliable products,” said Avtar Dhillion MD,
Executive Chairman of Emerald. “Our aim is to produce a product
pipeline of next-wave cannabis products that fit the better-defined
needs and preferences of consumers as Canada and other countries
that legalize medical and recreational cannabis use.”
Although cannabis is not presently federally
legal in the United States for commercial purposes, it is still the
most important "first to file" jurisdiction for intellectual
property generation and protection activity pertaining to cannabis
and cannabinoids. The Patent Cooperation Treaty permits Emerald to
file Canadian and international versions of these US patent
applications in 152 member countries worldwide over the coming
year.
About Emerald Health Therapeutics,
Inc.
Emerald Health Therapeutics, Inc. (TSXV: EMH;
OTCQX: EMHTF; Frankfurt: TBD) is a Licensed Producer under Canada’s
Access to Cannabis for Medical Purposes Regulations. Its 50%-owned
Pure Sunfarms in BC is completing a sophisticated 1.1 million
square feet greenhouse; its Agro-Biotech operation in Québec is
completing a 75,000 square feet indoor facility. Both facilities
are in commercial production. It has also contracted for
approximately 500 acres of hemp harvest in 2018 and 1000 acres in
2019 to 2022 with the goal of extracting low-cost cannabidiol
(CBD). Emerald’s team is highly experienced in life sciences,
product development, large-scale agri-business, and marketing, and
is focused on developing proprietary, value-added cannabis products
for medical and adult-use customers. Emerald is part of the Emerald
Health group, which is broadly focused on developing
pharmaceutical, botanical, and nutraceutical products that may
provide wellness and medical benefits by interacting with the human
body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more
information or contact:Rob Hill, Chief Financial Officer(800) 757
3536 Ext. #5
Ray Lagace, Investor Relations Manager(800) 757
3536 Ext. #5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include legalization of nonmedicinal cannabis in Canada and other
countries; eligibility of products for launch in Canada;
availability of products to the public; regulatory changes;
potential for market growth; safety enhancement; expansion of
research and development; future product development; future
filings for patent protection; acceptance of filings; grant of
patent rights; production capacity of various facilities; and
expansion of facilities; and anticipated production costs.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, failure to obtain regulatory approvals,
including approval of patent filings; efficacy of safety features;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labour;
demand for products; as well as the risk factors described in the
Company’s annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Jul 2023 to Jul 2024